FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches.

The article offers information on the U.S. Food & Drug Administration (FDA) Modernization Act 2.0. It discussed about transitioning preclinical research beyond animal models and toward human cells, organoids; artificial intelligence/machine learning (AI/ML)-based approaches to improve the translation of potential therapeutics from the bench to the bedside; and the potential of human-induced pluripotent stem cells & organoids.